• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

NeuroPhage Pharmaceuticals

edit

NeuroPhage Pharmaceuticals, Inc., a biotechnology company, develops disease-modifying therapies for the treatment of neurodegenerative diseases. The company develops a protein disaggregation platform for the treatment of Alzheimer’s, Parkinson’s, Huntington’s, amyotrophic lateral and multiple sclerosis, and other neurodegenerative diseases. It offers NPT001, a drug candidate for Alzheimer’s disease to disaggregate existing plaque in preclinical animal models. The company was founded in 2006 and is headquartered in Cambridge, Massachusetts.

Recent Milestones

edit

• 
  NeuroPhage Pharmaceuticals received $6.4M in Private Equity funding. (5/6/13)
  Posted 5/7/13 at 3:54am via finsmes.com
• 
  NeuroPhage Pharmaceuticals received $9M in Series B funding. (3/8/12)
  Posted 3/11/12 at 7:23pm via finsmes.com
• 
  NeuroPhage Pharmaceuticals — closed a $12.4M Series B round (3/2/11)
  Posted 3/3/11 at 8:26am via masshightech.com
• 
  NeuroPhage Pharmaceuticals received $12.4M in Series B funding. (3/1/11)
  Posted 3/1/11 at 8:10pm via neurophage.com
• 
  NeuroPhage Pharmaceuticals added Jonathan Solomon as President and CEO.
  Posted 3/1/11 at 8:10pm

Videos

Screenshots

edit

Sources

1. NeuroPhage Pharmaceuticals closes $12.4M Series B round (neurophage.com) [edit]
2. NeuroPhage Pharmaceuticals Raises $9.0M in Series B-1 Funding (finsmes.com) [edit]
3. NeuroPhage Pharmaceuticals Raises $6.4M in Equity Financing (finsmes.com) [edit]
New NeuroPhage funding to back move to Alzheimer's trial (masshightech.com) [edit]